Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | KIF5B | P33176 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17063662 | 0.87 | MKNK1 (0.77) | MKNK1LCKRETKDRROCK2 | |
| SCHEMBL16961583 | 0.87 | MKNK1 (0.77) | MKNK1RETKDR | |
| SCHEMBL15921201 | 0.86 | MKNK1 (1.00) | MKNK1LCK | |
| SCHEMBL17063668 | 0.86 | MKNK1 (0.75) | MKNK1LCKRETKDRROCK2 | |
| SCHEMBL16961903 | 0.86 | MKNK1 (0.75) | MKNK1LCKRETKDRROCK2 | |
| SCHEMBL29919772 | 0.84 | MKNK1 (0.72) | MKNK1ROCK2 | |
| SCHEMBL28936225 | 0.84 | MKNK1 (0.72) | MKNK1ROCK2 | |
| SCHEMBL28936235 | 0.84 | MKNK1 (0.72) | MKNK1LCKROCK2 | |
| SCHEMBL29919730 | 0.84 | MKNK1 (0.72) | MKNK1LCKROCK2 | |
| SCHEMBL28936127 | 0.83 | MKNK1 (0.71) | MKNK1RETKDRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951175-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma AG (DE) | 2017-10-04 | — | — | EP | claimed |
| US-9556181-B2 | Substituted pyrazolopyrimidinylamino-indazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-31 | — | — | US | claimed |
| US-20160002245-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-07 | — | — | US | claimed |
| EP-2951175-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2951175-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-9556181-B2 | Substituted pyrazolopyrimidinylamino-indazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160002245-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002245-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | VEGFA, PGF, MKI67 | MKNK1 1172/4885LCK 1211/4885PDPK1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.